Bexarotene Topical

Major

Bexarotene Topical Mercaptopurine Purinethol® An increased risk of hepatotoxicity Details Bexarotene Topical Mestranol Decreased contraceptive effectiveness Details Bexarotene Topical Methacycline An increased risk of pseudotumor cerebri (benign intracranial hypertension) Details Bexarotene Topical Methotrexate Jylamvo An increased risk of hepatotoxicity, an increased methotrexate exposure, an increased risk of methotrexate-related severe adverse... Details Bexarotene Topical Minocycline Amzeeq An increased risk of pseudotumor cerebri (benign intracranial hypertension) Details Bexarotene Topical Nifedipine Adalat® Reduced NIFEdipine exposure Details Bexarotene Topical Nomegestrol Decreased contraceptive effectiveness Details Bexarotene Topical Norelgestromin Decreased contraceptive effectiveness Details Bexarotene Topical Norethindrone Aygestin Decreased contraceptive effectiveness Details Bexarotene Topical Norgestimate Decreased contraceptive effectiveness Details Bexarotene Topical Norgestrel Decreased contraceptive effectiveness Details Bexarotene Topical Oliceridine Olinvyk Reduced oliceridine exposure and reduced efficacy of oliceridine Details Bexarotene Topical Omadacycline Nuzyra An increased risk of pseudotumor cerebri (benign intracranial hypertension) Details Bexarotene Topical Oxytetracycline An increased risk of pseudotumor cerebri (benign intracranial hypertension) Details Bexarotene Topical Palovarotene Sohonos Increased risk of hypervitaminosis A Details Bexarotene Topical Rolitetracycline An increased risk of pseudotumor cerebri (benign intracranial hypertension) Details Bexarotene Topical Rotavirus Vaccine, Live An increased risk of infection by the live vaccine Details Bexarotene Topical Sarecycline Seysara An increased risk of pseudotumor cerebri (benign intracranial hypertension) Details Bexarotene Topical Segesterone Decreased contraceptive effectiveness Details Bexarotene Topical Tetracycline Achromycin V® An increased risk of pseudotumor cerebri (benign intracranial hypertension) Details Bexarotene Topical Tigecycline Tygacil An increased risk of pseudotumor cerebri (benign intracranial hypertension) Details Bexarotene Topical Tramadol ConZip Reduced traMADol exposure and reduced efficacy of traMADol Details Bexarotene Topical Ulipristal Ella Decreased contraceptive effectiveness Details Bexarotene Topical Voriconazole Vfend Reduced voriconazole exposure and an reduced efficacy of voriconazole Details

Moderate

Bexarotene Topical Artemether Reduced artemether/lumefantrine exposure, reduced efficacy of artemether/lumefantrine and loss of antimalarial efficacy Details Bexarotene Topical Atorvastatin Atorvaliq Decreased atorvastatin plasma concentrations Details Bexarotene Topical Erythromycin Erythrocin Stearate Increased bexarotene exposure Details Bexarotene Topical Fosphenytoin Cerebyx Decreased plasma levels of bexarotene Details Bexarotene Topical Hydrocortisone Ala-Cort Reduced hydrocortisone exposure Details Bexarotene Topical Ketoconazole Extina Increased bexarotene exposure Details Bexarotene Topical Lumefantrine Reduced artemether/lumefantrine exposure, reduced efficacy of artemether/lumefantrine and loss of antimalarial efficacy Details Bexarotene Topical Phenobarbital Fidoquel Decreased plasma levels of bexarotene Details Bexarotene Topical Phenytoin Dilantin Decreased plasma levels of bexarotene Details Bexarotene Topical Rifampin Rifadin Decreased plasma levels of bexarotene Details Bexarotene Topical Vitamin A Aquasol A An increased risk of retinoid toxicity Details